Previous 10 | Next 10 |
MannKind's ( MNKD ) investors have had an interesting week. The drama from the activist campaign has seen a bit of a lull, but that does not mean that there was nothing happening. This week the company saw executives make some small buys of the company's stock, the announcement of a date for t...
Khiron Life Sciences ( OTCQB:KHRNF ) initiated with Speculative Buy rating at Alta. More news on: Khiron Life Sciences Corp., AMAG Pharmaceuticals, Inc., United Therapeutics Corporation, Healthcare stocks news, , Read more ...
United Therapeutics Corporation (UTHR) Q2 2019 Results Conference Call July 31, 2019 09:00 AM ET Company Participants James Edgemond - CFO Dr. Martine Rothblatt - Chairman and CEO Michael Benkowitz - President and COO Conference Call Participants Hartaj Singh - Oppenheimer ...
United Therapeutics ( UTHR ) Q2 results : Revenues: $373.6M (-16.0%). More news on: United Therapeutics Corporation, Healthcare stocks news, Earnings news and commentary, Read more ...
United Therapeutics (NASDAQ: UTHR ): Q2 Non-GAAP EPS of $3.63 beats by $0.89 ; GAAP EPS of $4.66 beats by $2.20 . More news on: United Therapeutics Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2019. "Our prostacyclin product franchise, consisting of Remodulin, Tyvaso, a...
United Therapeutics (NASDAQ: UTHR ) is scheduled to announce Q2 earnings results on Wednesday, July 31st, before market open. The consensus EPS Estimate is $2.74 (-37.2% Y/Y) and the consensus Revenue Estimate is $332.26M (-25.3% Y/Y). Over the last 2 years, UTHR has beaten EPS e...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2019 financial results before the market opens on Wednesday, July 31, 2019 . United Therapeut...
MannKind's ( MNKD ) shareholders have had an interesting week. The company made a move with debt, had a meeting with shareholder atavists, and saw a healthy recovery in scripts while coming off of a holiday week. With all of the happenings, the stock still sits right around a buck. Scripts ...
United Therapeutics Corporation ( UTHR ) is in an unstoppable downtrend that started in March. Since reporting fourth-quarter results on Feb. 28, selling accelerated in May when the company posted its first-quarter results for 2019. After revenues fell and losses mounted, should investor...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...